Protagonist Therapeutics gets a boost from SG Americas Securities LLC

Trending News ☀️

Protagonist Therapeutics ($NASDAQ:PTGX), Inc. is a clinical-stage biopharmaceutical company with a focus on developing novel therapies for gastrointestinal diseases. The company’s stock has seen a boost from SG Americas Securities LLC, who has increased their holdings in the company. Protagonist Therapeutics has been working on developing a treatment for celiac disease, a condition that affects the digestive system and can lead to serious health complications.

The company’s stock has seen an increase in recent months as investors have become more optimistic about the potential for the company’s products to be approved by the FDA. With the celiac disease treatment nearing completion of clinical trials, there is potential for significant upside in the stock price if the product is approved by the FDA.

Share Price

So far, media coverage has been mostly positive for the company. On Tuesday, PROTAGONIST THERAPEUTICS stock opened at $8.0 and closed at $8.4, up by 4.9% from its last closing price of $8.0.

VI Analysis

Companies with strong fundamentals are usually considered to have a long-term potential for growth. VI’s app makes analyzing a company’s fundamentals easy and simple. Based on the VI Star Chart, PROTAGONIST THERAPEUTICS has an intermediate health score of 5/10 with regard to its cashflows and debt. This means that the company is likely to be able to pay off its debt and fund future operations.

However, the company is weak in terms of profitability. PROTAGONIST THERAPEUTICS is classified as a ‘cheetah’ company, which is a type of company that has achieved high revenue or earnings growth but is considered less stable due to lower profitability. Investors interested in such companies may be looking for high growth potential, but they should be aware of the risks involved.

VI Peers

The company’s competitors include LogicBio Therapeutics Inc, Landos Biopharma Inc, and IO Biotech Inc.

– LogicBio Therapeutics Inc ($NASDAQ:LOGC)

LogicBio Therapeutics Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare diseases. The company’s lead product candidate is LB-1001, which is in clinical development for the treatment of adenosine deaminase severe combined immunodeficiency (ADA-SCID). The company has a market cap of $67.57 million and a return on equity of -82.33%. LogicBio Therapeutics is headquartered in Boston, Massachusetts.

– Landos Biopharma Inc ($NASDAQ:LABP)

Landos Biopharma Inc is a clinical-stage biopharmaceutical company dedicated to developing and commercializing first-in-class oral therapeutics for the treatment of autoimmune diseases. The company’s lead product candidate, BT-11, is a first-in-class, orally-active, selective inhibitor of losartan-sensitive, non-competitive alpha9beta1 integrin. BT-11 is being developed as a novel, disease-modifying therapy for patients with primary sclerosing cholangitis (PSC), a chronic, progressive, orphan liver disease. PSC is characterized by inflammation and fibrosis of the bile ducts, which can lead to liver failure and death. There are currently no FDA-approved treatments for PSC. Landos is currently enrolling patients in a Phase 2 clinical trial of BT-11 in patients with PSC. The company has demonstrated proof-of-concept in a Phase 2a clinical trial in patients with relapsing remitting multiple sclerosis (RRMS), an autoimmune disease of the central nervous system. Landos is currently preparing to initiate a Phase 2b clinical trial of BT-11 in patients with RRMS.

Landos Biopharma Inc has a market cap of 14.4M as of 2022, a Return on Equity of -64.92%. The company is dedicated to developing and commercializing first-in-class oral therapeutics for the treatment of autoimmune diseases. The company’s lead product candidate, BT-11, is a first-in-class, orally-active, selective inhibitor of losartan-sensitive, non-competitive alpha9beta1 integrin. BT-11 is being developed as a novel, disease-modifying therapy for patients with primary sclerosing cholangitis (PSC), a chronic, progressive, orphan liver disease. PSC is characterized by inflammation and fibrosis of the bile ducts, which can lead to liver failure and death. There are currently no FDA-approved treatments for PSC. Landos is currently enrolling patients in a Phase 2 clinical trial of BT-11 in patients with PSC. The company has demonstrated proof-of-concept in a Phase 2a clinical trial in patients with relapsing remitting multiple sclerosis (RRMS), an autoimmune disease of the central nervous system. Landos is currently preparing to initiate a Phase 2b clinical trial of BT-11 in patients with RRMS.

– IO Biotech Inc ($NASDAQ:IOBT)

Incyte Corporation is a biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule drugs to treat serious unmet medical needs, primarily in oncology. The company has a market capitalization of $72.04 million and a negative return on equity of 20.77%. Incyte is headquartered in Wilmington, Delaware, and has operations in the United States, Europe, and Asia.

Summary

Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a focus on developing and commercializing oral peptide therapeutics for the treatment of serious diseases. In addition, Protagonist is developing oral peptide therapeutics targeting other disease areas, including autoimmune diseases, inflammatory bowel disease and cancer. Investing in Protagonist Therapeutics offers investors the potential to participate in the upside of a clinical-stage biopharmaceutical company with a promising lead product candidate. In addition, the company’s pipeline of other oral peptide therapeutics targeting other disease areas provides investors with additional upside potential.